retatrutide glp-1 gip glucagon triple agonist receptor Sweet Temptation, bitter Truth: Diabetes in the Research Spotlight Retatrutide Obesity Triple Agonist Targeting
Description
Exp Clin Endocrinol Diab
The velocity of innovationwith over 100 active development programs, weekly patent filings, and continuous clinical readoutsdemands intelligence infrastructure that can synthesize signals across disparate data sources in real time
GLP-1 isnt just about hunger
Diabetes Care 2016;39:15011509 [DOI] [PubMed] [Google Scholar] 66.Buse JB, Rosenstock J, Sesti G, et al
